scholarly journals Data Mining Methods to Improve Clinical Trials in Diabetic Patients

2018 ◽  
Vol 06 (04) ◽  
Author(s):  
Chandeep Kaur ◽  
Olufemi Muibi Omisakin
Author(s):  
I.M. Burykin ◽  
◽  
G.N. Aleeva ◽  
R.Kh. Khafizianova ◽  
◽  
...  
Keyword(s):  

2020 ◽  
Author(s):  
Sanaa Bardaweel

Recently, an outbreak of fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. As the coronavirus pandemic rages, drug discovery and development become even more challenging. Drug repurposing of the antimalarial drug chloroquine and its hydroxylated form had demonstrated apparent effectiveness in the treatment of COVID-19 associated pneumonia in clinical trials. SARS-CoV-2 spike protein shares 31.9% sequence identity with the spike protein presents in the Middle East Respiratory Syndrome Corona Virus (MERS-CoV), which infects cells through the interaction of its spike protein with the DPP4 receptor found on macrophages. Sitagliptin, a DPP4 inhibitor, that is known for its antidiabetic, immunoregulatory, anti-inflammatory, and beneficial cardiometabolic effects has been shown to reverse macrophage responses in MERS-CoV infection and reduce CXCL10 chemokine production in AIDS patients. We suggest that Sitagliptin may be beneficial alternative for the treatment of COVID-19 disease especially in diabetic patients and patients with preexisting cardiovascular conditions who are already at higher risk of COVID-19 infection.


2021 ◽  
pp. 111144
Author(s):  
Yuzhou Wang ◽  
Zhengfei Li ◽  
Huanxin Chen ◽  
Jianxin Zhang ◽  
Qian Liu ◽  
...  

IEEE Access ◽  
2020 ◽  
Vol 8 ◽  
pp. 228598-228604
Author(s):  
Yongqiang Zhao ◽  
Shirui Pan ◽  
Jia Wu ◽  
Huaiyu Wan ◽  
Huizhi Liang ◽  
...  

Procedia CIRP ◽  
2016 ◽  
Vol 57 ◽  
pp. 259-264 ◽  
Author(s):  
Robert Glawar ◽  
Zsolt Kemeny ◽  
Tanja Nemeth ◽  
Kurt Matyas ◽  
Laszlo Monostori ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document